Connor, Clark & Lunn Investment Management Ltd. Sio Gene Therapies Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$0.55 - $1.47 $9,936 - $26,557	-18,066 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$1.29 - $2.36 $147,388 - $269,641	-114,255 Reduced 86.35%	18,066 $23,000
Q3 2021 Nov 12, 2021	SELL	$1.81 - $2.7 $73,781 - $110,060	-40,763 Reduced 23.55%	132,321 $287,000
Q2 2021 Aug 12, 2021	SELL	$2.07 - $2.89 $7,569 - $10,568	-3,657 Reduced 2.07%	173,084 $473,000
Q1 2021 May 13, 2021	BUY	$2.34 - $3.44 $137,847 - $202,646	58,909 Added 49.99%	176,741 $461,000
Q4 2020 Feb 16, 2021	BUY	$1.91 - $5.63 $225,059 - $663,394	117,832 New	117,832 $328,000

Others Institutions Holding SIOX

# of Institutions

Shares Held

147K

Call Options Held

Put Options Held

Act Capital Management, LLC Wayne, PA

147K
Shares

$0
0.06% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

View Full List

About Sio Gene Therapies Inc.

Ticker SIOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,975,200
Description
Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical S...

More about SIOX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account